Media about us

• Coda Therapeutics raise additional $20M for series B

  25 July 2012 Private Equity Hub

  CoDa Therapeutics has raised an additional $20 million from RusnanoMedInvest in a second close of its Series B financing round. This brings the total Series B Round to nearly $40 million following the first close late last year. All current investors, including Domain Associates, GBS Ventures and BioPacificVentures participated. San Diego-based CoDa is a biopharmaceutical company working to develop drug therapies for wounds that do not heal properly, including venous leg and diabetic foot ulcers.

• Russia’s Rusnano, Domain Invest $40 Million In San Diego’s CoDa

  24 July 2012 Ksenia Galouchko, Bloomberg

  

  Russian Nanotechnologies, the state- run technology holding, and Domain Associates, a U.S. venture fund, are investing about $40 million in San Diego-based biopharmaceutical company CoDa Therapeutics.

• RUSNANO and Domain to Collaborate on Investments in Health Sciences Projects

  07 March 2012 Nanowerk News

  

  RUSNANO and Domain Associates, a U.S. venture capital firm specializing in leading-edge life sciences technologies, today announced a partnership that will spur modernization of the Russian healthcare market by bringing next-generation pharmaceuticals, medical devices and diagnostics to Russia.

• Rusnano, US fund to invest $760 mln in pharma venture

  06 March 2012 Megan Davies, Reuters

  

  Russian state technology firm Rusnano is teaming up with a U.S. venture fund to invest around $760 million in a number of U.S. healthcare and pharmaceuticals firms, establish a manufacturing facility in Russia and bring new drugs to the Russian market.

• Domain partners with RusNano on $760M biotech investment plan

  06 March 2012 John Carroll, Fierce Biotech

  

  The Russians are back. After capturing the attention of the nanobio crowd with a few hefty investments in the U.S., RusNano is now partnering with Domain Associates on a $760 million initiative that will invest in about 20 life sciences companies and construct a pharma manufacturing center in Russia to produce next-gen therapies.

• Rusnano Teams Up With U.S. Fund Domain to Invest in Life Science

  06 March 2012 Jason Corcoran, BLOOMBERG

  

  Russian Nanotechnologies Corp. plans to work with Domain Associates, a U.S. venture fund, to invest $760 million in U.S. life science companies and build facilities in Russia.